Wave Life Sciences Ltd (WVE)

NASDAQ
3.495
-0.205(-5.54%)
  • Volume:
    12,810
  • Day's Range:
    3.495 - 3.630
  • 52 wk Range:
    1.160 - 6.640

WVE Overview

Prev. Close
3.7
Day's Range
3.495-3.63
Revenue
40.31M
Open
3.61
52 wk Range
1.16-6.64
EPS
-2.04
Volume
12,810
Market Cap
307.34M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
601,935
P/E Ratio
-1.72
Beta
-0.525
1-Year Change
-38.02%
Shares Outstanding
86,820,111
Next Earnings Date
Nov 10, 2022
What is your sentiment on Wave Life Sciences Ltd?
or
Vote to see community's results!

Wave Life Sciences Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Analog Devices Earnings, Revenue Beat in Q3
    • ByInvesting.com-

    Investing.com - Analog Devices (NASDAQ:ADI) reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Analog Devices...

  • TJX Earnings Beat, Revenue Misses In Q2
    • ByInvesting.com-

    Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings per...

Wave Life Sciences Ltd Analysis

Wave Life Sciences Ltd Company Profile

Wave Life Sciences Ltd Company Profile

Employees
237

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington’s disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuySell
Technical IndicatorsStrong SellStrong SellBuyStrong BuyStrong Sell
SummaryStrong SellStrong SellBuyStrong BuyStrong Sell
  • WVE (P) 0.00000000 5.15000000
    0
    • Hoping for $9.00 tomorow
      0
      • Bought 300 at $5.17. What is happening in this stock this morning?
        0
        • What a piece
          1
          • When will this hit $10
            2
            • 8.04 to 12.50
              1
              • This sucks
                1
              • facts
                0